SRR2932828
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- ANGIOGENESIS+0.330
- MYOGENESIS+0.270
- APICAL_JUNCTION+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.220
- ESTROGEN_RESPONSE_EARLY+0.200
- OXIDATIVE_PHOSPHORYLATION+0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- COAGULATION+0.170
Top 10 suppressed
- E2F_TARGETS-0.530
- ALLOGRAFT_REJECTION-0.430
- G2M_CHECKPOINT-0.430
- ANDROGEN_RESPONSE-0.230
- PROTEIN_SECRETION-0.230
- MITOTIC_SPINDLE-0.220
- MYC_TARGETS_V1-0.200
- HEDGEHOG_SIGNALING-0.190
- IL6_JAK_STAT3_SIGNALING-0.170
- INTERFERON_GAMMA_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303751 | — | — | 0.711 |
| 2 | SRR8518125 | — | F | 0.707 |
| 3 | f0f41799-29e8-43f9-b357-722df163e963 | — | — | 0.702 |
| 4 | SRR4296108 | — | cohortA1 | 0.687 |
| 5 | TCGA-A2-A0CP-01A-11R-A034-07 | — | A | 0.682 |
| 6 | MBCProject_0988_T1_RNA | — | B | 0.681 |
| 7 | 3698f158-b7ab-4ad0-9064-ee1269a17821 | — | — | 0.679 |
| 8 | SRR35579814 | — | A | 0.671 |
| 9 | TCGA-56-8622-01A-11R-2403-07 | — | cohortSQ1 | 0.663 |
| 10 | 59364db9-7bf7-4a15-9798-8e3886078012 | — | — | 0.658 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |